Roivant's FcRn drug IMVT-1402 fails Phase 2b lupus trial
read at Endpoints ↗Negative readoutNegative
Roivant announced that its FcRn-targeting antibody IMVT-1402 (imeroprubart) failed to meet primary endpoints in a Phase 2b trial in patients with lupus.
The study did not show improvement in disease symptoms compared with placebo, and the company said it will evaluate the data further.
The setback affects Roivant's autoimmune pipeline, where IMVT-1402 was a leading candidate, and may delay its plans to advance the drug.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Roivant reports Phase 2b lupus failure for an FcRn drug”
read at Endpoints ↗81 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that